---
title: "TP53-driven clonal evolution from bone marrow failure to leukemia in ERCC6L2 disease"
id: "medrxiv-13-intense-tp53-pathway-selection-drives-clonal-evolution-from-bone-marrow-failure"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-13-intense-tp53-pathway-selection-drives-clonal-evolution-from-bone-marrow-failure"
content_type: "clinical_feed_article"
specialty: "Hematology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.16.26363199v1?rss=1"
published_at: "2026-09-17T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# TP53-driven clonal evolution from bone marrow failure to leukemia in ERCC6L2 disease
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-13-intense-tp53-pathway-selection-drives-clonal-evolution-from-bone-marrow-failure
- **Specialty:** [Hematology](https://medichelpline.com/clinical-feed/hematology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.16.26363199v1?rss=1)
- **Published At:** 2026-09-17T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- ERCC6L2 disease (ED) is an inherited **bone marrow failure** syndrome that progresses predominantly to erythroid, **TP53**-mutated myeloid malignancy. The somatic evolutionary steps prior to leukemia were previously unclear. - The study analyzed 29 ED patients with longitudinal sampling, integrating whole-genome sequencing and single-cell RNA sequencing to map clonal dynamics over time. - ED displays early, intense, and recurrent selection for **TP53-mutant clones**: TP53 mutations in ED were more frequent, more often multiple per patient, and showed faster age-related expansion than in Shwachman-Diamond syndrome (SDS), a comparison disease also prone to TP53 mutations. - All TP53-negative ED patients in the cohort were children, indicating that TP53-mutant clones accumulate with age in ED. - Multiple TP53 mutations were present before overt malignancy and exceeded the burden seen in sporadic TP53-mutated myeloid neoplasia, indicating pronounced preleukemic TP53 pathway selection. - Mutation type shifted with disease stage: **missense** TP53 mutations dominated the bone marrow failure phase, whereas **non-missense** (likely truncating or loss-of-function) TP53 mutations were observed in patients with malignant disease, consistent with biallelic inactivation during progression. - Outside TP53, the somatic driver landscape in ED was highly restricted; **PPM1D** was the only other recurrent driver gene identified in the cohort. - Despite ERCC6L2’s role in DNA repair, ED did not exhibit an ED-specific mutational signature; rather, mutations reflected **age-associated** mutational processes. - Malignant progression was associated with acquisition of complex karyotypes, recurrent chromosome 5, 7, and 12p losses, enrichment of these abnormalities in **erythroid progenitors**, and localized hypermutation (kataegis), supporting a model of branched, erythroid-predominant clonal evolution. - The findings position ED as a model disease demonstrating preleukemic dependency on p53-pathway attenuation and provide a longitudinal view of how TP53-mutated leukemia can arise and evolve. - Data from individual patients are restricted under participant consent and EU GDPR, but summary-level variant calls, allele frequencies, and clonal composition are provided in the manuscript and supplements. IRB approval and participant consent were obtained for the study.
## Clinical Analysis & Structured Key Points
Intense TP53 pathway selection drives clonal evolution from bone marrow failure to leukemia in ERCC6L2 disease | medRxiv Skip to main content Intense TP53 pathway selection drives clonal evolution from bone marrow failure to leukemia in ERCC6L2 disease View ORCID Profile Suvi P.M. Douglas , View ORCID Profile Ilse Kaaja , View ORCID Profile Ina I Ikonen , View ORCID Profile Laura Langohr , View ORCID Profile Jessica Koski , View ORCID Profile Marja Hakkarainen , Lotta Katainen , View ORCID Profile Gisela Barbany , View ORCID Profile Eva Hellstrom-Lindberg , View ORCID Profile Kirsi Jahnukainen , View ORCID Profile Sakari Kakko , View ORCID Profile Timo Siitonen , View ORCID Profile Riitta Niinimaki , View ORCID Profile Esa Pitkanen , View ORCID Profile Ulla Wartiovaara-Kautto , View ORCID Profile Outi Kilpivaara doi: https://doi.org/10.64898/2026.09.16.26363199 Suvi P.M. Douglas 1 University of Helsinki, Helsinki, Finland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Suvi P.M. Douglas Ilse Kaaja 1 University of Helsinki, Helsinki, Finland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ilse Kaaja Ina I Ikonen 1 University of Helsinki, Helsinki, Finland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ina I Ikonen Laura Langohr 1 University of Helsinki, Helsinki, Finland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Laura Langohr Jessica Koski 1 University of Helsinki, Helsinki, Finland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Jessica Koski Marja Hakkarainen 2 Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Marja Hakkarainen Lotta Katainen 1 University of Helsinki, Helsinki, Finland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Gisela Barbany 3 Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Gisela Barbany Eva Hellstrom-Lindberg 3 Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Eva Hellstrom-Lindberg Kirsi Jahnukainen 2 Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Kirsi Jahnukainen Sakari Kakko 4 Oulu University Hospital and University of Oulu, Oulu, Finland Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Sakari Kakko Timo Siitonen 4 Oulu University Hospital and University of Oulu, Oulu, Finland Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Timo Siitonen Riitta Niinimaki 4 Oulu University Hospital and University of Oulu, Oulu, Finland Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Riitta Niinimaki Esa Pitkanen 1 University of Helsinki, Helsinki, Finland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Esa Pitkanen Ulla Wartiovaara-Kautto 2 Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ulla Wartiovaara-Kautto Outi Kilpivaara 1 University of Helsinki, Helsinki, Finland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Outi Kilpivaara For correspondence: outi.kilpivaara{at}helsinki.fi Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract ERCC6L2 disease (ED) is an inherited bone marrow failure (BMF) syndrome that progresses almost exclusively to erythroid, TP53-mutated myeloid malignancy, but the somatic evolution underlying the progression in patients is unknown. We characterized the genetic landscape of 29 ED patients with longitudinal sampling, integrating whole-genome and single-cell RNA sequencing, and compared the findings with Shwachman-Diamond syndrome (SDS), another TP53 mutation-prone disease, to define somatic evolution across disease stages. ED was defined by early, intense, and recurrent selection of TP53-mutant clones: TP53 mutations were more frequent, more often multiple, and showed steeper age-related expansion than in SDS; all TP53-negative ED patients were children. The burden of multiple TP53 mutations exceeded that of sporadic TP53-mutated myeloid neoplasia and was evident before malignancy. Missense mutations dominated the BMF phase, whereas non-missense mutations were seen in patients with malignancy, consistent with biallelic second hits, marking a stage-dependent shift in p53 inactivation. Beyond TP53, the landscape was strikingly restricted, with PPM1D as the only recurrent driver gene. Notably, despite the DNA-repair function of ERCC6L2, no ED-specific mutational signature emerged; but instead reflected age-associated processes. Malignant progression was accompanied by a complex karyotype, recurrent chromosome 5, 7, and 12p losses enriched in erythroid progenitors, and kataegis, consistent with branched, erythroid-predominant clonal evolution. Our findings establish ED as a paradigm of preleukemic dependency on p53-pathway attenuation. As progression is driven predominantly by p53 and captured longitudinally from the earliest clones, ED offers a model of how TP53-mutated leukemia arises and evolves, with relevance beyond a rare syndrome. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study has been approved by Helsinki University Central Hospital ethics review committee (#206/13/03/03/2016, amendment 2023, and HRUHLAB2). All samples from living individuals are derived after written informed consent. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The data generated in this study derive from patients with a rare disease and are therefore individually identifiable. In accordance with the terms of the participants' written informed consent and the approval of the Coordinating Ethics Committee of the Helsinki University Hospital, and under the EU General Data Protection Regulation, these data cannot be deposited in a public repository. Summary-level data, including variant calls, allele frequencies, and clonal composition supporting the findings of this study, are provided in the manuscript and its supplementary files. Funder Information Declared Research Council of Finland , 349760 , 322675 iCAN Digital Precision Cancer Medicine Flagship Sigrid Jusélius Foundation, https://ror.org/00ckakm23 Cancer Foundation Finland Children′s Cancer Foundation AAMU Finnish Special governmental grant for health sciences and research Incyte Biosciences Finnish Cultural Foundation, https://ror.org/027xav248 Instrumentarium Science Foundation, https://ror.org/02w907m39 Doctoral Programme for Biomedicine Biomedicum Helsinki Foundation Päivikki and Sakari Sohlberg Foundation, https://ror.org/03bj5da63 Emil Aaltosen Säätiö, https://ror.org/005rt3g54 K. Albin Johanssons stiftelse, https://ror.org/03arxxe13 Paulo Foundation, https://ror.org/048e7gn38 Ida Montinin Säätiö, https://ror.org/0269hs475 Finnish Hematology Association Blood Disease Research Foundation Orion Research Foundation sr Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted September 17, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Intense TP53 pathway selection drives clonal evolution from bone marrow failure to leukemia in ERCC6L2 disease Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Intense TP53 pathway selection drives clonal evolution from bone marrow failure to leukemia in ERCC6L2 disease Suvi P.M. Douglas , Ilse Kaaja , Ina I Ikonen , Laura Langohr , Jessica Koski , Marja Hakkarainen , Lotta Katainen , Gisela Barbany , Eva Hellstrom-Lindberg , Kirsi Jahnukainen , Sakari Kakko , Timo Siitonen , Riitta Niinimaki , Esa Pitkanen , Ulla Wartiovaara-Kautto , Outi Kilpivaara medRxiv 2026.09.16.26363199; doi: https://doi.org/10.64898/2026.09.16.26363199 Share This Article: Copy Citation Tools Intense TP53 pathway selection drives clonal evolution from bone marrow failure to leukemia in ERCC6L2 disease Suvi P.M. Douglas , Ilse Kaaja , Ina I Ikonen , Laura Langohr , Jessica Koski , Marja Hakkarainen , Lotta Katainen , Gisela Barbany , Eva Hellstrom-Lindberg , Kirsi Jahnukainen , Sakari Kakko , Timo Siitonen , Riitta Niinimaki , Esa Pitkanen , Ulla Wartiovaara-Kautto , Outi Kilpivaara medRxiv 2026.09.16.26363199; doi: https://doi.org/10.64898/2026.09.16.26363199 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Hematology Subject Areas All Articles Addiction Medicine (618) Allergy and Immunology (903) Anesthesia (334) Cardiovascular Medicine (4822) Dentistry and Oral Medicine (479) Dermatology (416) Emergency Medicine (650) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1632) Epidemiology (15962) Forensic Medicine (33) Gastroenterology (1203) Genetic and Genomic Medicine (7055) Geriatric Medicine (733) Health Economics (1066) Health Informatics (5054) Health Policy (1435) Health Systems and Quality Improvement (1773) Hematology (587) HIV/AIDS (1346) Infectious Diseases (except HIV/AIDS) (16298) Intensive Care and Critical Care Medicine (1174) Medical Education (670) Medical Ethics (155) Nephrology (725) Neurology (7286) Nursing (368) Nutrition (1082) Obstetrics and Gynecology (1243) Occupational and Environmental Health (1005) Oncology (3613) Ophthalmology (1054) Orthopedics (398) Otolaryngology (457) Pain Medicine (472) Palliative Medicine (139) Pathology (709) Pediatrics (1804) Pharmacology and Therapeutics (737) Primary Care Research (768) Psychiatry and Clinical Psychology (5910) Public and Global Health (9766) Radiology and Imaging (2429) Rehabilitation Medicine and Physical Therapy (1455) Respiratory Medicine (1249) Rheumatology (642) Sexual and Reproductive Health (772) Sports Medicine (578) Surgery (780) Toxicology (107) Transplantation (305) Urology (292)
## Related Clinical Research

- [Whole-genome sequencing identifies rare coding variants and key genes associated with acute myeloi](https://medichelpline.com/clinical-feed/medrxiv-21-prioritizing-genes-and-rare-protein-coding-variants-in-acute-myeloid-leukemia.md)
- [Structured aerobic exercise linked to lower cancer recurrence and improved survival](https://medichelpline.com/clinical-feed/medical-news-today-0-aerobic-exercise-could-help-improve-outlook-after-cancer-treatment.md)
- [Obesity-associated inflammation and cancer: mechanisms linking adipose immune changes to tumor risk](https://medichelpline.com/clinical-feed/frontiers-in-immunology-6-obesity-associated-inflammation-and-cancer-molecular-mechanisms-evidence-gaps.md)
- [8-hour time-restricted eating yields greater weight loss but not consistent blood pressure benefits](https://medichelpline.com/clinical-feed/medical-news-today-0-16-8-intermittent-fasting-best-for-weight-loss-but-not-for-blood-pressure.md)
- [Molecular Response, Event-Free Survival, and Treatment-Free Remission in Myeloproliferative Neopla](https://medichelpline.com/clinical-feed/pubmed-42758401.md) (DOI: 10.1007/s11899-026-00790-5)

## Navigation
- [← Back to Hematology Feed](https://medichelpline.com/clinical-feed/hematology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.